Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2014-04-10 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
PR INNATE PHARMA R&D UPDATE IN NEW YORK 10th April 2014
Investor Presentation Classification · 95% confidence The document is titled "HIGHLIGHTS FROM INNATE PHARMA'S R&D UPDATE" and details corporate strategy, clinical development plans (lirilumab, IPH2201), and a brief financial update (cash position as of Q1 2014). This content structure—a summary of research and development progress, often presented to investors or analysts—strongly suggests an Investor Presentation (IP). Although it is presented as a press release format, the core content is a detailed update on R&D milestones, which aligns best with the Investor Presentation definition, rather than a general Earnings Release (ER) which focuses purely on financial results, or a Call Transcript (CT) which is the verbatim speech. Given the depth of R&D pipeline information, IP is the most appropriate classification.
2014-04-10 English
NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 4 AVRIL 2014
Share Issue/Capital Change Classification · 95% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 AVRIL 2014" (New number of shares and voting rights as of April 4, 2014). It explicitly states it is published in accordance with French Commercial Code and AMF (Autorité des marchés financiers) regulations to report the total number of shares and voting rights. This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing related to share structure, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general 'Regulatory Filing' (RNS). Since it details the exact count of shares and voting rights, which is a direct consequence of capital structure, SHA is the most precise fit. It is not an earnings release, an annual report, or a management discussion.
2014-04-07 French
Cohort Expansion
Regulatory Filings Classification · 95% confidence The document is clearly labeled as a "PRESS RELEASE" and announces a specific operational update: the start of the cohort expansion phase of a clinical trial involving two drug candidates (lirilumab and nivolumab). This type of announcement, detailing clinical progress, partnerships, and company news outside of mandatory periodic financial filings (like 10-K or IR), typically falls under general regulatory announcements or investor news. Since it is a press release announcing operational progress rather than a formal financial report, dividend notice, or management change, the most appropriate category is the general regulatory announcement fallback, RNS (Regulatory Filings). It is not a Call Transcript (CT), Earnings Release (ER), or a specific financial report (10-K, IR). Given its nature as a public announcement of a business milestone, RNS is the best fit.
2014-03-31 English
Extension de cohorte
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific operational update: the start of a cohort extension in a Phase I clinical trial involving Innate Pharma's drug candidates. It provides details about the trial, the drug mechanism, licensing agreements, and includes standard disclaimers and contact information typical of a corporate announcement. This type of announcement, which is a formal communication to the market about a business or operational event (not a full financial report like 10-K or IR, nor a transcript or presentation), fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate announcement, although it shares characteristics with an Earnings Release (ER) in format, it lacks financial results. Given the options, RNS serves as the best general regulatory/corporate announcement category for non-standard filings.
2014-03-31 French
Nombre d'actions
Share Issue/Capital Change Classification · 95% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 24 MARS 2014" (New number of shares and voting rights as of March 24, 2014) and explicitly states it is published in accordance with French Commercial Code and AMF regulations (Autorité des marchés financiers). It details the total number of shares and voting rights. This type of mandatory disclosure regarding the total share capital and voting rights is a specific corporate action announcement. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with an announcement related to capital structure changes or share issuance/status, fitting best under 'Share Issue/Capital Change' (SHA) or potentially a general regulatory filing (RNS). Since it reports the current total share count, which is a fundamental aspect of capital structure, SHA is the most precise fit, although it is not a transaction itself, but a reporting of the resulting structure. Given the options, SHA covers changes/updates to the share base. If it were purely a notification of a transaction, POS might apply, but this is a periodic regulatory update on the total count. I will classify it as SHA as it directly concerns the number of shares and voting rights.
2014-03-28 French
eligibilité PEA
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2014, announcing that Innate Pharma confirms its eligibility for the PEA-PME (a French regulated investment scheme). This announcement relates to the company's structure and compliance with specific financial/regulatory criteria (employee count, revenue/balance sheet thresholds) set by French law (Décret n° 2014-283). This type of announcement, which details compliance status or specific corporate structure qualifications rather than routine financial results (ER/IR) or management changes (MANG), fits best under a general regulatory or corporate announcement category. Since it is not a standard filing like 10-K, AR, or a specific transaction notice (DIV, SHA, POS), and it is a formal announcement of a regulatory status confirmation, it is classified as a Regulatory Filing (RNS) as the most appropriate general category, although it touches upon capital structure eligibility. Given the short length and press release format, it is not a comprehensive report.
2014-03-28 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.